Literature DB >> 25025570

Regulation of alternative splicing of CD44 in cancer.

Lubomir Prochazka1, Radek Tesarik2, Jaroslav Turanek2.   

Abstract

CD44 is a hyaluronan binding cell surface signal transducing receptor that influences motility, cell survival and proliferation as well as the formation of tumor microenvironment. CD44 contains two variable regions encoded by variable exons. Alternative splicing, which is often deregulated in cancer, can produce various isoforms of CD44 with properties that may have different tissue specific effects and therefore even diverse effects on cancer progression. This review summarizes and puts together all major regulators of alternative splicing of CD44 in cancer that have been documented so far and that have an experimentally proved effect on CD44 isoform switching. It is important to better understand the mechanisms of alternative splicing of CD44, where all the variability of CD44 originates, to be able to explain the isoform switching and occurrence of variant isoforms of CD44 (CD44v) in cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alternative splicing; CD44; CD44v; CSC; EMT; Isoform switch

Mesh:

Substances:

Year:  2014        PMID: 25025570     DOI: 10.1016/j.cellsig.2014.07.011

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  71 in total

1.  Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis.

Authors:  Shin-Ae Kang; Nafis Hasan; Aman P Mann; Wei Zheng; Lichao Zhao; Lynsie Morris; Weizhu Zhu; Yan D Zhao; K Stephen Suh; William C Dooley; David Volk; David G Gorenstein; Massimo Cristofanilli; Hallgeir Rui; Takemi Tanaka
Journal:  Mol Ther       Date:  2015-03-27       Impact factor: 11.454

2.  ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity.

Authors:  Donatas Stakišaitis; Milda Juknevičienė; Albertas Ulys; Dalia Žaliūnienė; Daiva Stanislovaitienė; Ramunė Šepetienė; Anželika Slavinska; Kęstutis Sužiedėlis; Vita Lesauskaitė
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

3.  Prognostic Significance of CD44 and Orthopedia Homeobox Protein (OTP) Expression in Pulmonary Carcinoid Tumours.

Authors:  George Papaxoinis; Daisuke Nonaka; Ciara O'Brien; Benjamin Sanderson; Piotr Krysiak; Wasat Mansoor
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 4.  Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.

Authors:  Yongmin Yan; Xiangsheng Zuo; Daoyan Wei
Journal:  Stem Cells Transl Med       Date:  2015-07-01       Impact factor: 6.940

Review 5.  Influence of transcriptional variants on metastasis.

Authors:  Joice De Faria Poloni; Diego Bonatto
Journal:  RNA Biol       Date:  2018-07-24       Impact factor: 4.652

6.  SNRPA enhances tumour cell growth in gastric cancer through modulating NGF expression.

Authors:  Ning Dou; Dong Yang; Shijun Yu; Binghao Wu; Yong Gao; Yandong Li
Journal:  Cell Prolif       Date:  2018-07-24       Impact factor: 6.831

7.  Extracellular Domains I and II of cell-surface glycoprotein CD44 mediate its trans-homophilic dimerization and tumor cluster aggregation.

Authors:  Madoka Kawaguchi; Nurmaa Dashzeveg; Yue Cao; Yuzhi Jia; Xia Liu; Yang Shen; Huiping Liu
Journal:  J Biol Chem       Date:  2020-01-22       Impact factor: 5.157

8.  Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas.

Authors:  Chongxian Hou; Yukitomo Ishi; Hiroaki Motegi; Michinari Okamoto; Yafei Ou; Jiawei Chen; Shigeru Yamaguchi
Journal:  J Neurooncol       Date:  2019-09-10       Impact factor: 4.130

Review 9.  The role of RNA processing and regulation in metastatic dormancy.

Authors:  Kimberly A Parker; Nathaniel J Robinson; William P Schiemann
Journal:  Semin Cancer Biol       Date:  2021-03-26       Impact factor: 15.707

10.  Altered Expression of MBNL Family of Alternative Splicing Factors in Colorectal Cancer.

Authors:  Nazila Navvabi; Pavla Kolikova; Petr Hosek; Frantisek Zitricky; Azita Navvabi; Ondrej Vycital; Jan Bruha; Richard Palek; Jachym Rosendorf; Vaclav Liska; Pavel Pitule
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.